48.27
0.84 (1.77%)
0.84 (1.77%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.84 | 1.77% | 48.27 | 17:15:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 47.51 | 47.30 | 48.61 | 48.27 | 47.43 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 48.27 | 49.87 | 1.60 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 12,262 | 1,286,134 | $ 47.98 | $ 61,711,992 | 1,269,012 | 12.71 - 48.61 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:17:12 | formt | 29,000 | $ 48.27 | USD |
Halozyme Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.53B | 135.18M | 120.15M | $ 195.99M | $ 75.12M | -0.50 | 296.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 43.46 | 48.61 | 42.54 | 45.79 | 1,801,353 | 4.81 | 11.07% |
| 1 Month | 43.87 | 48.61 | 41.02 | 44.02 | 1,050,425 | 4.40 | 10.03% |
| 3 Months | 30.81 | 48.61 | 27.21 | 38.80 | 1,954,113 | 17.46 | 56.67% |
| 6 Months | 28.98 | 48.61 | 25.17 | 34.56 | 1,447,855 | 19.29 | 66.56% |
| 1 Year | 19.90 | 48.61 | 12.71 | 27.79 | 1,494,983 | 28.37 | 142.56% |
| 3 Years | 17.82 | 48.61 | 12.71 | 22.13 | 1,112,774 | 30.45 | 170.88% |
| 5 Years | 10.31 | 48.61 | 6.96 | 17.68 | 1,233,569 | 37.96 | 368.19% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
